ReviewInternational journal of bioprinting2020
3D Bioprinting: The Roller Coaster Ride to Commercialization.
Review in International journal of bioprinting, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Review
- A Pill That Prints-An Ingestible Bioprinter for Non-Invasive Structured Bioink Deposition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Development and Quantitative Evaluation of a Novel AutonomousIEEE transactions on automation science and engineering : a publication of the IEEE Robotics and Automation Society · 2025Article
- The promising approach of 3D bioprinting for diabetic foot ulcer treatment: A concise review of recent developments.Heliyon · 2024Review
- Review
- Functional materials of 3D bioprinting for wound dressings and skin tissue engineering applications: A review.International journal of bioprinting · 2023Review
- Three-Dimensional Printing of an Apigenin-Loaded Mucoadhesive Film for Tailored Therapy to Oral Leukoplakia and the Chemopreventive Effect on a Rat Model of Oral Carcinogenesis.Pharmaceutics · 2022Article
- Multiparametric Material Functionality of Microtissue-Based In Vitro Models as Alternatives to Animal Testing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Development ofFrontiers in bioengineering and biotechnology · 2022Review
- Microfluidic Cell Transport with Piezoelectric Micro Diaphragm Pumps.Micromachines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Three-dimensional (3D) bioprinting as a technology is being researched and applied since 2003. It is actually several technologies (inkjet, extrusion, laser, magnetic bioprinting, etc.) under an umbrella term "3D bioprinting." The versatility of this technology allows widespread applications in several; however, after almost 20 years of research, there is still a limited number of cases of commercialized applications. This article discusses the potential for 3D bioprinting in regenerative medicine, drug discovery, and food industry, as well as the existing cases of companies that create commercialized products and services in the aforementioned areas and even in fashion, including their go-to-market route and financing received. We also address the main barriers to creating practical applications of 3D bioprinting within each sphere the technology that is being studied for.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.